Research into Alzheimer’s disease has witnessed a significant breakthrough with the investigational therapy blarcamesine, developed by Anavex Life Sciences. Recent findings from a phase 2b/3 clinical trial indicate that this drug not only reduces amyloid-β biomarkers but also slows the rate of brain atrophy in patients with early Alzheimer’s disease.  In this randomized, double-blind, placebo-controlled […]

Anavex Life Sciences hasannounced promising results from an extension study of their investigational therapy, Anavex 2-73 (blarcamesine), for treating Parkinson’s disease dementia. The extension study, a continuation of the Phase 2 ANAVEX 2-73-PDD-001 trial, demonstrated significant reductions in symptom severity and improved overall patient health over a one-year period.  The Phase 2 trial initially involved […]